Tag: Cancer: Leukemia
ASH: Black Race Linked to Poorer Survival in AML
Among AML patients treated on Alliance protocols, Blacks versus Whites had inferior disease-free, overall survival
Predictors of Late Effects in Young AML Survivors Explored
Most common late effects were endocrine, cardiovascular, respiratory; likelihood of late effects up for those who underwent HSCT
Dasatinib + Blinatumomab Active for Ph-Positive ALL in Adults
Complete remission, overall survival seen in 98, 95 percent of patients in phase 2 study
Factors Associated With Suicide in Leukemia Identified
Risk factors include male sex, older age at diagnosis, White race
Measurable Residual Disease Negativity Tied to Survival in AML
AML patients without MRD have higher estimated rates of five-year disease-free, overall survival
Late Morbidity, Mortality Down for Survivors of Childhood ALL
Compared with 1970s, rate of subsequent malignant neoplasms lower with standard-risk 1990s-like therapy
Drug Combo Prolongs Survival in Acute Myeloid Leukemia
Findings seen for azacitidine + venetoclax in older patients ineligible for intensive chemotherapy
ASH Issues Guidelines on Newly Diagnosed AML in Older Adults
Antileukemic therapy recommended over supportive care for patients who are candidates for such therapy
Survivors of Adolescent, Young Adult ALL May Suffer Late Effects
Estimated 10-year cumulative incidence high for subsequent endocrine disease, cardiac disease
Good Diet May Cut Toxicity Risk in Treatment of Pediatric ALL
Greater intake of foods rich in antioxidants tied to lower rates of infection, mucositis during treatment
